Novel modulator of collagen synthesis and matrix metalloproteinases (MMPs) expression levels, boosting collagen synthesis and reducing MMPs expression levels in human fibroblasts without cytotoxicity

Prodrug of Vitamin E, modulating atherosclerotic and inflammatory events more efficiently than the unphosphorylated alpha-tocopherol

Specific inhibitor of aldose reductase

Novel potent and selective oxytocin receptor antagonist

Novel selective dual inhibitor of Cdk1/cyclin B and GSK-3β

Inhibitor of HSP90, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction

Peripherally acting µ-opioid antagonist

Novel lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) antagonist

Prodrug of ALX5407, a selective non-transportable inhibitor of the glycine transporter GlyT1

Potent GlyT-2 antagonist

Novel potent, selective, and orally bioavailable PI3Kdelta inhibitor

Novel Cannabinoid Receptor CB2 antagonist

The first covalent hCB2 antagonist/inverse agonist

Novel potent, selective, and orally bioavailable PI3Kdelta inhibitor

Novel GPR40 agonist with minimal CNS penetration, superior pharmacokinetic properties and in vivo efficacy comparable to AMG 837

Potent in vitro and in vivo inhibitor of fatty acid amide hydrolase (FAAH)

Potent FFA1 (GPR40) agonist, inhibiting insulin secretion from isolated pancreatic islets and reducing blood glucose levels

Novel highly potent inhibitor of human alpha/beta hydrolase domain 6 (hABHD6)

Reversible cholinesterase inhibitor used in the management of myasthenia gravis

Antibiotic against Serratia sp. ATCC 39006 (S39006) strain

Downregulator of genes associated with the translation machinery and fatty acid biosynthesis in Serratia, increasing expression of genes related to the uptake of L-proline after RNA-Seq of S39006 to be treated

Novel inducer of inactivation of eIF2-alpha by phosphorylating serine residue 51 in a dose- and time-dependent manner

0

Novel modulator of autophagy activity, triggering autophagy in an Atg5-dependent manner, recruiting Atg16 to the pre-autophagosomal site and causing LC3 lipidation

Natural thrombin (E.C. 3.4.21.5) inhibitor, suppressing melanin synthesis, regulating the ATM/ATR signaling pathway and the Skp2-p27 axis in human colon cancer cells

Novel PDE10 antagonist

Novel transient receptor potential type V1 (TRPV1) receptor antagonist

Novel disrupter of glucokinase-glucokinase regulatory protein (GK-GKRP) binding, inducing GK translocation from the nucleus to the cytoplasm in rats and blood glucose reduction in mice

Novel glucokinase activator, decreasing fasting and postprandial glycaemia

Novel selective IRE1α inhibitor

Potent and selective TRPV1 antagonist

Novel potent DPP-IV inhibitor

Novel potent and selective inhibitor of c-Kit

Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib, a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research.

Novel Disrupter of Glucokinase−Glucokinase Regulatory Protein (GK−GKRP) Binding

Novel highly specific phosphodiesterase 10A (PDE10A) ligand with good uptake in the striatum

Vanilloid receptor TRPV1 antagonist

Novel vanilloid receptor TRPV1 modulator

Novel vanilloid receptor TRPV1 modulator

Specific transient receptor potential ankyrin 1 (TRPA1) antagonist

Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $15.75 Total: $1,575.00 50 $18.20 Total: $910.00 25 $21.35 Total: $533.75 10 $25.20 Total: $252.00 5 $29.75 Total: $148.75

Cysteine trapping agent, protecting cysteines exposed to the aqueous environment from subsequently added mal-PEG

Radiation-protective agent, causing splenic vasodilation and blocking autonomic ganglia

NSAID (non-steroidal anti-inflammatory drug) and non selective COX inhibitor

Immunomodulator

Inhibitor of the re-uptake of norepinephrine and serotonin, inhibiting N-methyl-D-aspartate (NMDA) receptors

L-type calcium channel blocker

Anthelmintic agent against infections with the human hookworm

Light-activated DNA, RNA crosslinking agent

Potent A1/A2A adenosine receptor agonist, protecting against myocardial infarction

The most potent AMPA stabilizer

Novel rapid and specific inhibitor of electrophile-sensitive DEAD-box proteins with high selectivity over the wild-type enzyme

Potent allosteric activator of AMPK

Potent allosteric activator of the AMPK

Novel agonist of AMPK signaling

Novel Metallo-β-lactamase Inhibitor

Novel potent inhibitor of peroxiredoxin I (PrxI), increasing cellular ROS, leading to the activation of both mitochondria- and apoptosis signal-regulated kinase-1-mediated signaling pathways

Novel small molecule prodrug for use with SEAKER cells, exhibiting enhanced anticancer activity

Novel inhibitor of the replication of a disease-causing polyomavirus in cell culture

DNA polymerase lambda and beta inhibitor

Novel Anti-Wolbachia Agent with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis

Novel Neuraminidase (NA) inhibitor

Novel potent and selective leucyl-tRNA synthetase inhibitor

Inhibitor of TLR2-, TLR3-, TLR4- and TLR5-mediated TNF-α, IL-1β and IL-6

Novel anti-filariasis agent, being effective in killing Brugia malayi, B. pahangi, and Litomosoides sigmodontis worms

Anticholinergic agent

Novel Potent Anticonvulsant Agent with In Vitro Neuroprotection

Novel anticancer agent against metastatic Castration resistance and neuroendocrine variant prostate cancers (mCRPC/NEPC), exhibiting synergistic anticancer effect in combination with standard therapy docetaxel and cabazitaxel in mCRPC/NEPC, upregulating H

Novel angiogenesis agent, showing better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells, significantly increasing the angiogenic potential of vascular endothel

Peptide hormone that causes vasoconstriction and an increase in blood pressure

Novel inducer of autophagic cell death through regulating PI3 kinase class III/beclin 1/Atg-related proteins in cisplatin-resistant CAR human oral cancer cells

Novel activator of nuclear factor-erythroid-related factor 2 (Nrf-2)

Novel potent DYRK1A Kinase Inhibitor

Novel Potent and Selective DYRK1 Kinase Inhibitor

Natural inhibitor of NADH:ubiquinone oxidoreductase

Antimitotic antibiotic with antitumor, antiprotozoal, and antifungal activities

Novel Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae

Novel Broad-Spectrum Serine β-Lactamase Inhibitor, Strongly Potentiating Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii

Novel anti-AD agent, integrating Aβ-interacting and metal-binding fragments in a single molecular framework, exhibiting significant antioxidant activity and metal chelating ability, and also rescuing neuroblastoma N2A cells from Cu -induced Aβ neurotoxici

Novel multitarget directed anti-Alzheimer agent, showing an IC 50 value of 0.56 ± 0.02 μM for AChE and an IC 50 value of 1.17 ± 0.09 μM for BuChE

Novel highly potent orally bioavailable antiallergic agent, effectively suppressing mast cell degranulation in a dose-dependent manner (IC50, 2.54 nM for RBL-2H3 cells; 48.28 nM for peritoneal mast cells (PMCs))

Novel dose-dependent antiangiogenic agent

Analogue of the marine sponge natural product oroidin, suppresses biofilm formation and enhancing control of copper-resistant Xanthomonas euvesicatoria on pepper

Novel Potent and Nontoxic Antibiotic Adjuvant

Novel anticancer agent, showing most significant anti-cancer activity against prostate cancer cells with IC50 values of 8.8 µM and 9.5 µM in PC-3 and DU-145 cells, respectively

Novel covalent anti-cancer toxin, targeting β-tubulin and covalently modifyng Cys239 within the colchicine binding site

Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC)

Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC)

Novel broad-spectrum antifungal agent, also exhibiting good fungicidal activity against both fluconazole-sensitive and -resistant Candida albicans cells and having potent inhibition activity against Candida albicans biofilm formation and hyphal growth, in

Novel antifungal agent, inhibiting C. neoformans growth at submicromolar levels, being effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and being not antagonistic with currently approved antifungal

Novel antileishmanial agent against L. amazonensis promastigotes (IC 50 = 15.52 ± 3.782 μM) and intracellular amastigotes (IC 50 = 4.10 ± 1.136 μM), 50% cytotoxicity concentration at 84.01 ± 3.064 μM against BALB/c peritoneal macrophages, and 20.49-fold s

Novel antileishmanial agent, strongly inhibiting recombinant CYP51 from L. donovani, displaying activity against L. donovani intracellular amastigotes with an IC50 value of 0.53 μM

Novel idebenone analog, demonstrating significantly higher potency ex vivo, and significantly lower cytotoxicity, than idebenone in the treatment of Leber's Hereditary Optic Neuropathy (LHON)

Novel anti-MERS-CoV agent against virus-infected Huh7 cells

Novel antioxidant, binding copper in a unique manner compared to other chelates proposed to treat Alzheimer's disease and protecting HT-22 neuronal cells from cell death induced by Aβ + copper(II)

Novel anti-SARS-CoV-2 agent, displaying in vitro antiviral activity with IC 50 0.016 µM and Mpro inhibition activity with IC 50 0.013 µM, showing potent activity against human TMPRSS2 and furin enzymes with IC 50 0.05, and 0.08 µM, respectively

Novel antitubercular agent, exerting growth inhibition of Mtb during parasitism of host macrophages

Novel cellular anticancer agent, exhibiting 7.9-341.7-fold antiproliferative activities against four cell lines, Aspc-1 (human colon adenocarcinoma cells), H358 (human nonsmall cell lung cancer cells), HCT116 (human colorectal adenocarcinoma cells), and S

Novel anticancer agent, targeting PPARγ and HDAC4, being cytotoxic to CCRF-CEM cells (CC50 = 2.8 μM), inducing apoptosis, and causing DNA fragmentation, modulating the expression of c-Myc, cleaving caspase-3, and causing in vivo tumor regression in CCRF-C

Novel tumor-targeting cytotoxic agent

Cyclooxygenase inhibitior

AP1510 is a potent cell-permeable ligand for human FKBP12. AP1510 regulates protein-protein interactions through dimerization.

Novel highly potent and selective α4β2 nAChR antagonist

Inhibitor of both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation

Novel highly potent and selective Src_%28gene%29>Src kinase inhibitor

Novel inhibitor of the gatekeeper mutant of BCR-ABL, suppressing in vitro resistance

Potent and selective antitumor agent, effectively depleting cellular Fe, resulting in transferrin receptor-1 up-regulation, ferritin down-regulation, and increased expression of the potent metastasis suppressor, N-myc downstream regulated gene-1

Novel inhibitor of the Ap4A phosphorylase (Rv2613c) of Mycobacterium tuberculosis (Mtb)

Novel inhibitor of PCAF bromodomain/Tat-AcK50 association

Selective A2a adenosine receptor agonist

Novel inhibitor of PCAF bromodomain/Tat-AcK50 association

Novel potent and selective oxytocin receptor antagonist

N-Type calcium channel inhibitor

Histamine H3 receptor antagonist

Potent aminopeptidase N/CD13 (APN) inhibitor

Novel extremely potent inhibitor of APN activity in vitro, selective against other zinc-dependent enzymes such as matrix metalloproteases, and possessed limited cytotoxicity against Ad293 cells and favorable physicochemical and metabolic stability propert

Novel inducer of endogenous ApoA-I, protecting against atherosclerotic lesion development in ApoE-/- mice, upregulating the apolipoprotein A-I gene expression, enhancing its function of promoting cholesterol efflux, ABCA1 expression and activation of PPAR

Novel apolipoprotein E4 (apoE4) stabilizer, showing activity in an IL-6 and IL-8 cytokine release assay

Potent inhibitor of Bcl-2 and Mcl-1, acting as a BH3 mimetic

Inhibitor of HMG-CoA-reductase, promoting apoptosis of myeloma cells in vitro

Novel inducer of cell death by activating apoptosis in cancer cells

Novel anticancer agent, arresting MCF-7 cell growth at G2/M phase and S phase, dose dependent increasing in the mitochondrial membrane potential (ΔΨm) and ROS levels, decreasing in Gal-1 protein levels

Aminoglycoside antibiotic used in veterinary medicine

Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing

Novel tumor calibrated inhibitor, showing unique polypharmacology and strongly improved therapeutic index in fly and human MTC xenograft models

First-in-class inhibitor of APS reductase (APSR), a critical enzyme in the assimilation of sulfate for the biosynthesis of cysteine and other essential sulfur-containing molecules

Prodrug of APX-001A, the first-in-class inhibitor of the fungal protein Gwt1

Inactive analog of pyrabactin used as the negative controller

Selective blocker of the Aquaporin-1 ion channel conductance, slowing cancer cell migration

Novel agonist of the water channel aquaporin-1 (AQP1)

Novel SH2-​containing inositol 5-​phosphatase (SHIP 1) modulator

Novel Antiandrogen, Suppressing Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth

Novel AR antagonist, targeting the AR AF2, showing excellent AR antagonistic activity (IC 50 = 0.47 μM) and peptide displacement activity (IC 50 = 18.05 μM)

Novel potent androgen receptor (AR) degrader, exhibiting excellent AR binding affinity (85%) and AR degradation efficacy at 30 μM

Novel Rho kinase inhibitor

Novel inverse agonist of Mas G-protein signaling, dose-dependently inhibiting inositol 1,4,5-trisphosphate accumulation in AdMas-infected cells, and attenuating the sarcomeric organization and cell enlargement observed in Mas overexpressing myocytes

Novel 5-hydroxytryptamine 1B (5-HT 1B ) autoreceptor antagonist

Novel immunosuppressant and monocarboxylate transporter inhibitor, reducing immune responses both in vitro and in vivo, maintaining long-term graft survival, and inducing operational tolerance

Novel inhibitor of lactate transporters (monocarboxylate transporters; MCTs)

Highly potent CK2α inhibitor (K(i) = 0.5 nM), revealing high selectivity for CK2α in a panel of 140 protein kinases

Highly potent and selective fluorescent probe of Rho kinase (ROCK)

Anticancer agent, inducing apoptosis mediated at least in part by the ERS pathway and inhibiting hepatoma tumor growth

Negative control for ARCC-4, binding androgen receptors (AR) without inducing degradation.

Long-acting beta-2 adrenergic agonist

Long-acting beta-2 adrenergic agonist

Potent tumor-homing tripeptide, targeting heat shock protein 70 (HSP70)

Novel selective inhibitor of PREP, displaying great selectivity over FAP, while also not inhibiting the DPPs.

Novel inhibitor of Ark1, the fission yeast member of the conserved Aurora kinase family

P2T (P2YADP) purinoceptor antagonist

Selective ecto-ATPase inhibitor, preventing metabolism of P2 purinoceptor agonists

Natural inhibitor of recombinant purified ClpXP and ClpYQ AAA+ proteases, exhibitung potent antibacterial activity against H. pylori, including multidrug-resistant strains

Regulator and promotor of immune functions, enhancing the role of macrophages, inhibiting bacteria growth, improving the protein metabolism, and regulating liver function

Novel dual inhibitor of the fatty acid amide hydrolase (FAAH) and the cyclooxygenase (COX) enzymes

Novel selective estrogen receptor degrader (SERD), inducing regression in a tamoxifen-resistant breast cancer xenograft

Novel potent and selective BRAF inhibitor

Selective alpha-7 agonist

The first human arylsulfatase A reversible inhibitor, impairing mouse oocyte fertilization

Inhibitor of the inflammatory responses via NF

Non-steroidal selective estrogen receptor modulator (SERM)

Novel Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers

Inhibitor of D-amino acid oxidase (DAAO)

Inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake, significantly restoring decreased insulin-like growth factor 1 and fibroblast growth factor 2 mRNA levels in dorsal root ganglion and spinal cord, respectively

Potent factor Xa inhibitor with significant oral anticoagulant activity

Novel GPR119 agonist, potentiating insulin secretion from rat islets and having potent anti-diabetic effects in ICR and diabetic db/db mice

Second-generation potent orally-active thrombopoietin (TPO) receptor agonist

Novel Foxo1 inhibitor, exerting anti-diabetic and anti-hypertriglyceridemic effects by improving blood glucose and triglyceride metabolism at the gene expression level

Novel SHIP2 inhibitor, increasing Akt phosphorylation, glucose consumption, and glucose uptake in L6 myotubes, specifically upregulating the GLUT1 gene

Novel GPR40 agonist

Novel Receptor-interacting Protein Kinase 2 (RIP2) Inhibitor

Selective inhibitor of aurora kinases (AKs)

Novel angiogenesis inhibitor, directly binding to acid ceramidase 1 (ASAH1)

Novel inhibitor of inositol-requiring enzyme 1 (IRE-1), also inhibiting G protein-coupled receptor kinase 6 (GRK6)

Natural Suppressor of MMP-2-Mediated Migration and Invasion by Targeting FAK and JAK-STAT Signaling Cascades

Novel, Potent, Selective, and Brain-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Modulating Brain Inflammation In Vivo

Novel modulator of acetylcholine receptor function, promoting the in vitro relaxation of β2-adrenoreceptor desensitized tracheas

Novel, Potent, Selective, and Direct Acid Sphingomyelinase (ASM) Inhibitor with Antidepressant Activity

Novel Permanently-charged Sodium Channel Blocker, Showing Robust Efficacy, a Rapid Onset and Long Duration of Action

Novel potent GPR17 agonist

Novel slow-onset, tight binding, potent asparagine synthetase (ASNS) inhibitor

Selective progesterone receptor modulator

Novel antifungal agent against Aspergillus isolates

Novel dual A2A/A1 AR antagonist

Novel tropomyosin-related kinase A (TrkA) inhibitor for the oral treatment of pain due to osteoarthritis of the knee

Novel long-acting muscarinic antagonist (LAMA), showing more selective inhibition of bronchoconstriction against salivation and more rapid onset of action than tiotropium bromide

Novel potent Aspergillus hyphal growth inhibitor

Selective antagonist for the cholecystokinin receptor CCKA

Novel cholecystokinin antagonist

Novel cholecystokinin antagonist

Natural antineoplastic agent, targeting cathepsin and inducing autophagy effects in breast cancer cells

Natural inhibitor of pollen development in Arabidopsis thaliana, also inhibiting dihydroxy-acid dehydratase (DHAD)

Natural luciferase inhibitor

Natural inhibitor of glutamic oxaloacetate transaminase 1 (GOT1), suppressing glutamine metabolism, making PDAC cells sensitive to oxidative stress and inhibiting cell proliferation, exhibiting potent in vivo antitumor activity in an SW1990-cell-induced x

Novel potent anticancer agent, inhibiting the growth of CRC bulk and sensitized FOLFOX-resistant cells

Novel near-infrared (NIR) probe for imaging β-amyloid (Aβ) plaques or Tau tangles

Novel anti-Alzheimer’s agent, inhibiting amyloid β aggregation, β-secretase, and tau aggregation

Novel AKAP1/PKA modulator, inducing UCP1 expression and thermogenesis

Inhibitor of HIV-reverse transcriptase activity

Natural endogenous inhibitor of nitric oxide synthases (NOS), also inhibiting arginine transport and increasing oxygen free radicals, mitochondrial dysfunction and transforming growth factor beta (TGFβ) expression, exhibiting a strong association with car

Novel inhibitor of αSyn fibrillization, blocking fibril growth and suppressing A53T αSyn neurotoxicity

The First Small-molecule Opioid Pan Antagonist with Nanomolar Affinity at Mu, Delta, Kappa and Nociceptin Opioid Receptors.